Taylor & Francis Group
Browse

Cost-effectiveness analysis of nivolumab plus cabozantinib versus sunitinib as first-line therapy in advanced RCC.

Download (1.5 MB)
figure
posted on 2022-06-27, 07:34 authored by Jianxin Pang, Peihao Wu, Yanqing Jiang, Junyan Wu, Kaifeng Qiu, Ruizhe Liu

 Figure S1. Kaplan–Meier curves and modelled curves. 

History

Usage metrics

    Immunotherapy

    Categories

    Keywords

    sunitinibcabozantinib,nivolumabrenal cell carcinomacost-effectiveness

    Licence

    CC BY-NC-ND 4.0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC